The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease
1Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA. Electronic address: pmartin2@med.miami.edu.
2Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
3Department of Gastroenterology, Hepatology Unit & Instituto de Investigación La Fe, Hospital Universitari i Politècnic La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Valencia, Spain; School of Medicine, University of Valencia, Valencia, Spain.
4Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden; Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden.
5Division of Nephrology, Maggiore Hospital and Foundation IRCCC Cà Granda Ospedale Maggiore Policlinico, Milano, Italy.
6Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
7Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory of Transitional Medicine on Liver Cirrhosis, National Clinical Research Center for Digestive Diseases, Beijing, China.
8Departments of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France; INFINITY- Inserm U1291-CNRS U5051, Toulouse, France; Université Paul Sabatier, Toulouse, France.
9Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia.
10Division of Clinical Gastroenterology and Hepatology, Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, Brazil.
11Hepatology Department, Hopital Cochin, Université Paris Descartes, Paris, France.
12Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
13Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, Rhode Island, USA.
14Tufts Medical Center, Division of Nephrology, Boston, Massachusetts, USA.
15Kidney Disease: Improving Global Outcomes (KDIGO), Brussels, Belgium.
16Department of Nephrology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. Electronic address: michel.jadoul@saintluc.uclouvain.be.
Abstract
Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy or with a kidney transplant. Since the publication of the Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2018, advances in HCV management, particularly in the field of antiviral therapy and treatment of HCV-associated glomerular diseases, coupled with increased usage of HCV-positive kidney grafts, have prompted a reexamination of the 2018 guideline. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection.